Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer

NCT00001269 Phase 1 COMPLETED

This is a phase I study to determine the maximal tolerated dose of IL-3 given alone or sequentially with GM-CSF following FLAC chemotherapy in metastatic breast cancer patients.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	COMPLETED
Enrolment	100
Start date	1991-05
Completion	2001-02

Conditions

• Breast Neoplasms
• Neoplasm Metastasis

Interventions

• IL-3

Countries

United States